Neurology Main > Neuroimmunology & Multiple Sclerosis
ln

FAQ
Glossary
Research
- Clinical Trials
Treatment
- Cyclophosphamide (Cytoxan)
- First Line Disease Modifying Therapies
- Intravenous Immunoglobulin (IVIG)
- Methotrexate
- Mitoxantrone (Novantrone)
- Natalizumab (Tysabri)
- Rituximab (Rituxan)
- Solu-Medrol

Appointments and Referrals

Department Chair
- Michael Racke, MD
Faculty
- Mary Pat Bartoszek, CNP
- Aaron Boster, MD
- D. Joanne Lynn, MD
- Jacqueline Nicholas, MD
- Colleen O'Connell, CNP
Infusion Nurses
- Lori Atwood, RN
- Cynthia Hunter, RN
- Nancy, Ficco, RN
Research Staff
- Misty Regula
- Erin Marshall

Contact Us

Currently Enrolling Clinical Trials in MS
ln

The Neuroimmunology and Multiple Sclerosis Division at The Ohio State University Medical Center is committed to improving the lives of MS patients through new treatments and innovative care. We continually initiate new clinical trials to help us meet this goal. Please visit this site often to determine if you or someone you know may be eligible to participate in one of our clinical trials. Without research and research volunteers there will be no advancements against this disease.

ACT-128800 - click here to expand or contract details

ACT-128800. Phase IIb dose finding and safety trial exploring an oral selective S1P1 receptor modulator (possibly less cardiac and pulmonary side effects compared to Fingolimod).

Inclusion:

  • McDonald RRMS, age 18-55 inclusive, EDSS 0-5.5 inclusive
  • 1 attack in last 12 months OR 2 attacks in last 24 months OR 1+ Gad lesion on screening MRI
  • No MS attack or high dose steroids in the last 30 days

Exclusion:

  • Primary progressive MS
  • treatment in the last 30 days with steroids, B-blocker, diltiazem, verapamil, digoxin
  • IFN, GA, cyclosporine, sirolimus, cellcept, TPE, live vaccines in last 3 months
  • imuran, methotrexate, NTZ, IVIG, daclizumab in last 6 months
  • cytoxan, mitoxantrone, cladribine, Rituxan or alemtuzeumab EVER
  • negative vericella-zoster antibody test
  • history of cancer (except excised basal or squamous cell skin lesions)
  • history of poorly controlled DM, MI in last 6 months, valvular dz, heart failure, COPD

Coordinator/s: Melissa Wilson (614)293-6468 and Jamie McGowan (614)247-6856

 

ACP-001 - click here to expand or contract details

Accelerated Cure Project (ACP-001)- A Longitudinal, Case-Control Study to Collect Medical and Epidemiological Data and Blood

Inclusion:

  • A patient with at least 1 CNS event (MS, TM, ADEM, ON or NMO) OR a blood relative of a patient with a CNS event can serve as a Case subject
  • Any person without a history or family history of a CNS event can serve as a control subject

Exclusion:

  • history of marrow transplant
  • evidence of neuro diseases other than those in inclusion

Coordinator/s: Jamie McGowan (614)247-6856

 

Novartis (PPMS) - click here to expand or contract details

Novartis (PPMS)- A double-blind, randomized, multicenter, placebo controlled, parallel-group study comparing the efficacy and safety of 1.25mg FTY720 administered orally once daily versus placebo

Inclusion:

  • PPMS- McDonald’s criteria (2005 revised)
    • 1 yr of disease progression plus two of the following: Positive brain MRI, Positive Spinal cord MRI, Positive CSF
  • Ages 25-65, inclusive, EDSS 3.5-6.0, Pyramidal FSS ≥ 2, Timed 25 foot walk< 30 seconds
  • Evidence of progression of disability in the 2 yrs prior to Screening (documented in EDSS scores)
  • First MS symptom onset between 2 and 10 years prior to baseline visit

Exclusion:

  • history or presence of malignancy
  • have received total lymphoid irridation or bone marrow transplantation
  • have been treated with: systemic corticosteroids or ACTH within 3 months prior, interferon-beta or glatiramer acetate within 3 months
  • immunosuppressive medications, immunoglobulins and/or monoclonal antibodies within 6 months

Coordinator/s: Lisa Hafer (614)293-7877

 

Estriol - click here to expand or contract details

Estriol- combination treatment with oral Estriol in combination with injectable Copaxone is efficacious as compared to Copaxone alone in RRMS over 24 month trial period.

Inclusion:

  • Females age 18-50,EDSS 0.0-4.5
  • Active RRMS defined by either:
    • A. at least two clearly identified relapses within 24 months prior tostudy entry, OR
    • B. at least one relapse within 24 months prior to study entry AND have a history of at least one gadolinium enhancing lesion on a T1brain or cord. MRI done at least 3 months before or 3 months after the clinical relapse.
  • Pts that are on Copaxone less than 2 months are eligible, patients that are on greater than 2 months need to wash off for 3 months for eligibility

Exclusion:

  • females who are or plan to be pregnant during 24 months of study, 3 months after completion or are w/in 6 months post partum
  • subjects must not be on oral contraceptives (OCP), hormone replacement therapy (HRT), progesterone IUDs or other hormones during
  • screening and during the 24 month enrollment period.
  • patients who smoke at any time during screening or during the 24 month enrollment period.

Coordinator/s: Lisa Hafer (614)293-7877

 

Exercise - click here to expand or contract details

Exercise and cognition in MS

Cross sectional evaluation of MS patients’ exercise and cognitive status. 15 minute research MRI, computerized neuropsych test, wear a pedometer for a week, participation in 1 structured interview.

Inclusion: any ambulatory MS patient.

(Dr. Prakash, Contact lab manager Gabriel (614)292-9568)

Rebif+Cellcept - click here to expand or contract details

Rebif+Cellcept- combination of Cell Cept with Rebif . Up-regulation of the MxA gene following the administration of Rebif® will be used as a surrogate marker of interferon bioactivity.

Inclusion:

  • age of 18 to 65, inclusive
  • Any patient who is eligible for interferon therapy
    • this includes RRMS and CIS patients

Exclusion:

  • participation in a clinical trial or received another investigational therapy in the last 9 days.
  • Previous or current use of CellCept including use in any type of solid organ transplantation.
  • Subject has received corticosteroids within 30 days prior to screening.
  • Subject has received cyclophosphamide or mitoxantrone ever.
  • Subject has received Imuran or methotrexate in the last 3 months.
  • Subject has received tysabri in the last 3 months

Coordinator/s: Lisa Hafer (614)293-7877

 

Tysabri - click here to expand or contract details

Improving MS fatigue with Tysabri- the objectives of this study are 1) To determine whether fatigued MS patients exhibit increased cerebral activation (as measured on functional MRI) compared to non-fatigued MS patients during a sustained cognitive task. 2) To determine if natalizumab (Tysabri) objectively improves cognitive fatigue in MS patients (as measured of functional MRI) by a cognitive task before and after drug treatment.

Patients will undergo computerized neuropsychological assessments and functional MRI scans on three occasions over the course of one year (baseline, 6 months and 12 months)

Inclusion:

  • R-handed, RRMS (McDonald’s) patients
  • disease duration < 5 years
  • age < 55
  • EDSS < 5.5
  • patient has be about to start tysabri, a decision made by the clinician independent of whether they are going to do a trial or not

Exclusion:

  • either treatment naïve or have been off other disease modifying therapies for 1 month
  • relapse free and without exposure to corticosteroids for at least 6 months.

Coordinator/s: Lisa Hafer (614)293-7877